The ACME Laboratories Ltd. (DSE:ACMELAB)
 75.20
 -1.40 (-1.83%)
  At close: Nov 3, 2025
The ACME Laboratories Income Statement
Financials in millions BDT. Fiscal year is July - June.
 Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year  | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 | 
|---|---|---|---|---|---|---|---|
Period Ending  | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 | 
| 34,746 | 31,932 | 26,948 | 23,858 | 20,770 | 19,004 | Upgrade   | |
Revenue Growth (YoY)     | 12.77% | 18.50% | 12.95% | 14.87% | 9.29% | 16.53% | Upgrade   | 
Cost of Revenue     | 20,168 | 18,715 | 16,045 | 14,458 | 12,772 | 11,766 | Upgrade   | 
Gross Profit     | 14,578 | 13,216 | 10,902 | 9,401 | 7,998 | 7,237 | Upgrade   | 
Selling, General & Admin     | 8,353 | 7,539 | 6,424 | 5,381 | 4,457 | 3,551 | Upgrade   | 
Other Operating Expenses     | 3.9 | 3.9 | 3.89 | 3.73 | -96.44 | 5.73 | Upgrade   | 
Operating Expenses     | 8,357 | 7,543 | 6,428 | 5,385 | 4,360 | 3,556 | Upgrade   | 
Operating Income     | 6,221 | 5,673 | 4,474 | 4,016 | 3,638 | 3,681 | Upgrade   | 
Interest Expense     | -2,863 | -2,283 | -1,426 | -1,293 | -1,585 | -1,765 | Upgrade   | 
Interest & Investment Income     | 5.55 | 5.55 | 6.99 | 5.73 | 18.01 | 31.96 | Upgrade   | 
Currency Exchange Gain (Loss)     | -388.43 | -388.43 | -197.48 | -91.93 | 18.62 | 38.11 | Upgrade   | 
Other Non Operating Income (Expenses)     | 450.71 | 199.91 | 32.71 | 55.34 | -16.38 | -9.64 | Upgrade   | 
EBT Excluding Unusual Items     | 3,425 | 3,207 | 2,891 | 2,692 | 2,073 | 1,976 | Upgrade   | 
Gain (Loss) on Sale of Assets     | -3.94 | -3.94 | 3.86 | 1.31 | 0.18 | 3.25 | Upgrade   | 
Asset Writedown     | - | - | -1.37 | - | - | - | Upgrade   | 
Other Unusual Items     | 0.65 | 0.65 | - | - | - | - | Upgrade   | 
Pretax Income     | 3,422 | 3,204 | 2,893 | 2,693 | 2,073 | 1,979 | Upgrade   | 
Income Tax Expense     | 1,019 | 747.54 | 589.65 | 582.25 | 504.27 | 528.93 | Upgrade   | 
Net Income     | 2,403 | 2,456 | 2,304 | 2,111 | 1,569 | 1,450 | Upgrade   | 
Net Income to Common     | 2,403 | 2,456 | 2,304 | 2,111 | 1,569 | 1,450 | Upgrade   | 
Net Income Growth     | -0.71% | 6.62% | 9.13% | 34.52% | 8.19% | 0.70% | Upgrade   | 
Shares Outstanding (Basic)     | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade   | 
Shares Outstanding (Diluted)     | 212 | 212 | 212 | 212 | 212 | 212 | Upgrade   | 
EPS (Basic)     | 11.36 | 11.61 | 10.89 | 9.98 | 7.42 | 6.85 | Upgrade   | 
EPS (Diluted)     | 11.36 | 11.61 | 10.89 | 9.98 | 7.42 | 6.85 | Upgrade   | 
EPS Growth     | -0.71% | 6.62% | 9.13% | 34.52% | 8.26% | 0.63% | Upgrade   | 
Free Cash Flow     | -1,406 | -2,162 | -4,001 | -615.35 | 915.26 | -958.2 | Upgrade   | 
Free Cash Flow Per Share     | -6.64 | -10.22 | -18.91 | -2.91 | 4.33 | -4.53 | Upgrade   | 
Dividend Per Share     | 3.500 | 3.500 | 3.300 | 3.000 | 2.500 | 2.500 | Upgrade   | 
Dividend Growth     | 6.06% | 6.06% | 10.00% | 20.00% | - | -28.57% | Upgrade   | 
Gross Margin     | 41.95% | 41.39% | 40.46% | 39.40% | 38.51% | 38.08% | Upgrade   | 
Operating Margin     | 17.90% | 17.77% | 16.60% | 16.83% | 17.52% | 19.37% | Upgrade   | 
Profit Margin     | 6.92% | 7.69% | 8.55% | 8.85% | 7.56% | 7.63% | Upgrade   | 
Free Cash Flow Margin     | -4.04% | -6.77% | -14.85% | -2.58% | 4.41% | -5.04% | Upgrade   | 
EBITDA     | 7,865 | 7,227 | 5,882 | 5,368 | 4,970 | 4,866 | Upgrade   | 
EBITDA Margin     | 22.63% | 22.63% | 21.83% | 22.50% | 23.93% | 25.61% | Upgrade   | 
D&A For EBITDA     | 1,644 | 1,554 | 1,407 | 1,352 | 1,332 | 1,185 | Upgrade   | 
EBIT     | 6,221 | 5,673 | 4,474 | 4,016 | 3,638 | 3,681 | Upgrade   | 
EBIT Margin     | 17.90% | 17.77% | 16.60% | 16.83% | 17.52% | 19.37% | Upgrade   | 
Effective Tax Rate     | 29.77% | 23.33% | 20.38% | 21.62% | 24.32% | 26.72% | Upgrade   | 
Advertising Expenses     | - | 178.77 | 146.59 | 138.99 | - | - | Upgrade   | 
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.